Ofer Lavie1, Angela Chetrit2, Ilya Novikov3, Siegal Sadetzki4. 1. Gyneco-oncology Unit, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel; Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. 2. Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Chaim Sheba Medical Center, Tel Hashomer, Israel. 3. Biostatistics Unit, Gertner Institute for Epidemiology & Health Policy Research, Chaim Sheba Medical Center, Tel Hashomer, Israel. 4. Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: siegals@gertner.health.gov.il.
Abstract
OBJECTIVE: Compare 5, 10 and 15 year survival in invasive epithelial ovarian cancer, between patients with and without BRCA1/2 germ line mutation in a nonselective group of patients diagnosed during 1994-99. METHODS: The analysis was based on 779 Jewish patients: 229 carriers to the Ashkenazi Jewish founder mutations in BRCA1 (185delAG; 5382insC) and BRCA2 (6174delT); and 550 non-carriers. Clinical characteristics were abstracted from the patients' medical records and vital status was updated through the National Population Registry up to 11/2015. The Kaplan-Meier method, log-rank tests, and Cox-regression model were used for survival analyses. RESULTS: By the end of the follow-up period, (range 1-20 years), 629 (80.7%) deaths occurred. While considerably higher survival was observed during the first 5 years from diagnosis among carriers compared to non-carriers (46.7% vs. 36.2%, p = 0.0004), the survival rates at 15 years were 22.3% vs. 21.8% respectively (p = 0.04). The age-adjusted hazard ratio for all-cause mortality of carriers versus non-carriers was 0.74 (95%CI 0.60-0.91) in the first 5 years. For women who survived 5 and 10 years, the age-adjusted hazard ratios for mortality during 5 additional years, of carriers compared to non-carriers, were 1.38 (95%CI 0.93-2.04) and 1.08 (95%CI 0.61-1.92), respectively. CONCLUSION: The results of this study, with up to 20 years follow-up, support studies with shorter follow-up that suggested that the advantage in survival observed among BRCA1/2 carriers during the first 5 years decreases over time. Clinically, this may have implications for follow-up and therapy, especially of new agents that are particularly effective in BRCA carriers.
OBJECTIVE: Compare 5, 10 and 15 year survival in invasive epithelial ovarian cancer, between patients with and without BRCA1/2 germ line mutation in a nonselective group of patients diagnosed during 1994-99. METHODS: The analysis was based on 779 Jewish patients: 229 carriers to the Ashkenazi Jewish founder mutations in BRCA1 (185delAG; 5382insC) and BRCA2 (6174delT); and 550 non-carriers. Clinical characteristics were abstracted from the patients' medical records and vital status was updated through the National Population Registry up to 11/2015. The Kaplan-Meier method, log-rank tests, and Cox-regression model were used for survival analyses. RESULTS: By the end of the follow-up period, (range 1-20 years), 629 (80.7%) deaths occurred. While considerably higher survival was observed during the first 5 years from diagnosis among carriers compared to non-carriers (46.7% vs. 36.2%, p = 0.0004), the survival rates at 15 years were 22.3% vs. 21.8% respectively (p = 0.04). The age-adjusted hazard ratio for all-cause mortality of carriers versus non-carriers was 0.74 (95%CI 0.60-0.91) in the first 5 years. For women who survived 5 and 10 years, the age-adjusted hazard ratios for mortality during 5 additional years, of carriers compared to non-carriers, were 1.38 (95%CI 0.93-2.04) and 1.08 (95%CI 0.61-1.92), respectively. CONCLUSION: The results of this study, with up to 20 years follow-up, support studies with shorter follow-up that suggested that the advantage in survival observed among BRCA1/2 carriers during the first 5 years decreases over time. Clinically, this may have implications for follow-up and therapy, especially of new agents that are particularly effective in BRCA carriers.
Authors: Sara Corvigno; Jared K Burks; Wei Hu; Yanping Zhong; Nicholas B Jennings; Nicole D Fleming; Shannon N Westin; Bryan Fellman; Jinsong Liu; Anil K Sood Journal: J Cancer Res Clin Oncol Date: 2021-09-02 Impact factor: 4.322
Authors: Felipe Leonardo Estati; Rafaela Pirolli; Viviane Teixeira Loiola de Alencar; Adriana Regina Gonçalves Ribeiro; Maria Nirvana Formiga; Giovana Tardin Torrezan; Dirce Maria Carraro; Andrea Paiva Gadelha Guimarães; Glauco Baiocchi; Alexandre André Balieiro Anastácio da Costa Journal: Ann Surg Oncol Date: 2020-11-21 Impact factor: 5.344
Authors: Orestis Tsonis; Fani Gkrozou; Konstantinos Vlachos; Minas Paschopoulos; Michail C Mitsis; Nikolaos Zakynthinakis-Kyriakou; Stergios Boussios; George Pappas-Gogos Journal: Ann Transl Med Date: 2020-12
Authors: Bernadette A M Heemskerk-Gerritsen; Antoinette Hollestelle; Christi J van Asperen; Irma van den Beek; Willemien J van Driel; Klaartje van Engelen; Encarna B Gómez Garcia; Joanne A de Hullu; Marco J Koudijs; Marian J E Mourits; Maartje J Hooning; Ingrid A Boere Journal: PLoS One Date: 2022-09-22 Impact factor: 3.752
Authors: Allison W Kurian; Paul Abrahamse; Irina Bondarenko; Ann S Hamilton; Dennis Deapen; Scarlett L Gomez; Monica Morrow; Jonathan S Berek; Timothy P Hofer; Steven J Katz; Kevin C Ward Journal: J Natl Cancer Inst Date: 2022-02-07 Impact factor: 11.816